A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the ...

News, features, and commentary about cancer-related issues ...

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

New research suggests childhood cancer survivors may experience accelerated biological aging from treatments, potentially ...

Shares fell, wiping out year-to-date gains in the company’s stock after it said the combination of giredestrant with Pfizer’s Ibrance didn’t meet its primary objective.

A positive story for those going through cancer treatment. The Houston-based non-profit CanCare is stepping in to fill the ...